| Availability: | |
|---|---|
| Quantity: | |
Morbus latior coverage – Xenogeneicus (humanus PBMC), allogeneicus MHC-partitus acutus, et lupus similis GVHD chronica exempla in promptu habet.
Fines quantitatis - Corpus pondus, rate superstes, GVHD score (0-10 scala cum statu, actu, fur, cute), serum autoantibodies (anti-dsDNA, IgG), proteinuria, histopathologia.
Mechanismus agitatae - Humanum PBMC exemplar pro therapeuticis humanis specialibus; exempla allogeneica pro T cellula mediata GVHD; exemplar chronicum pro pathologia autoantibody mediante.
Valor translationalis - Idealis ad probandos immunosuppressores (calcineurin inhibitores, mTOR inhibitores), biologicos (anti-TNF, anti-IL-6R), et therapiae cellae substructio.
IND-parati fasciculi notati - Studia administrari possunt ad normam GLP principiorum.
Humanum PBMC inductum acutum GVHD exemplar

B6 cellulae lienis inductae B6D2F1 aGVHD Model

DBA/2 lymphocyte Inductus B6D2F1 cGVHD Exemplar


• Efficacia experimentorum immunosuppressorum (tacrolimus, cyclosporinus, mycophenolatus, mofetilis, mTOR inhibitores) pro praeventioni et curatione GVHD
• Aestimatio biologicorum Nisl T cellularum (anti-CD3, anti-CD4), cytokinorum (anti-IL-6R, anti-TNF), et meatus co-stimulationis (CTLA-4-Ig)
• Expertio cellae therapiae substructio (Tregum, MSCs) et strategies anticorporum iuvant.
• Convalidatio target pro T activatione cellae, productione autoanticorpore, et pathologia multi-organi
• IND - pharmacologiam et toxicologiam studiis
Parameter |
Humanum PBMC aGVHD Model |
B6 → B6D2F1 aGVHD Model | DBA/2 → B6D2F1 cGVHD Model |
Species/Strain |
NSG mus (recipiens) |
B6 → B6D2F1 | DBA/2 → B6D2F1 |
Genus morbi |
Acutus (xenogeneicus) | Acutus (allogeneicus) | Chronica. |
Clavis terminos |
Corpus pondus, salvos, GVHD score | Superstes, GVHD score | Corpus pondus, salvos, GVHD score, serum IgG, anti-dsDNA, proteinuria, biochemia sanguinis, pathologia renis |
A1: Offerimus tria exempla matura: GVHD in NSG mures acutos humanos PBMC inductos, B6 splenem cellulam acutam GVHD in B6D2F1 mures inductos, et DBA/2 lymphocyte-inductas in mures B6D2F1 lymphocyte longos GVHD.
A2: Cellae immunes donator alloantigens vel xenoantigens agnoscit recipiens, inflammatio systemica et multi-organi damnum educitur et trigger. Pathologicis lineamentis acutis et chronicis GVHD perfecte recapitulant.
A3: Nos monitor corporis pondus, salvos rate et GVHD orci turpis. Pro vetustis GVHD, nos etiam serum dsDNA, IGG et interdum urinarii deprehendere, plus renum analysis pathologicae.
A4: Exemplar hPBMC aGVHD perstat 28 dies cum 1Gy irradiatione ante cellam injectionem. Exemplar B6 splenis cellae aGVHD per 60 dies decurrit. Exemplar cGVHD sumit usque ad 15 septimanas post translationi lymphocytae.